Zugriffszahlen seit März 2016. Zugriffszahlen aus dem Vorgängersystem werden nicht mitberücksichtigt.

Total Visits

Views
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia29

Total Visits Per Month

June 2021July 2021August 2021September 2021October 2021November 2021December 2021
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia1640010

Top country views

Views

Top cities views

Views